Although studies found that high expression of PD-L1, another biomarker of ICI response, was associated with a variety of clinical parameters, such as proliferation (Ki-67), Gleason Score, and androgen receptor expression (55), and was an independent biomarker in the prognosis of high-risk PCa patients who received adjuvant hormonal therapy after radical prostatectomy (56), the results of relevant clinical trials were unsatisfactory probably due to the tumor immunosuppressive microenvironment. This evidence concerns the gene MKI67 and posterior cortical atrophy.